Betta Pharmaceuticals Co., Ltd.

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This study looks at whether taking the targeted drug icotinib after surgery helps people with early-stage non-small cell lung cancer that has EGFR mutations live longer. Researchers will compare patients who received icotinib after complete tumor removal with those who only had r…

This trial tests an experimental drug called CFT8919 in people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to find the safest dose and see whether the drug can shrink tumors. Participants take CFT8919 capsules twice daily and undergo regular ch…

This study tests a combination of two drugs, MCLA-129 and ensartinib, in people with advanced solid tumors that cannot be cured. The drugs work by blocking certain proteins that help cancer grow. The trial has two phases: first to find the safest dose, then to see if the combo sh…

This study is testing an experimental drug called MCLA-129 in people with advanced solid tumors, including non-small cell lung cancer, head and neck cancer, and colorectal cancer. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-Met)…

This study is for people with advanced non-small cell lung cancer that has stopped responding to a type of targeted therapy called third-generation EGFR TKIs. Researchers want to see if giving chemotherapy first, followed by a newer targeted drug called befotertinib, can help con…

Researchers are studying how a single 200 mg dose of vorolanib, an experimental oral cancer drug, moves through the body in people with mild or moderate liver impairment compared with people whose livers work normally. The trial enrolls 36 participants split into three groups bas…

Researchers are studying whether rifampicin or itraconazole change how the body handles befotertinib, an oral medicine for lung cancer. Thirty-six healthy volunteers take a single dose of befotertinib alone, then again after several days of rifampicin or itraconazole. The study m…

Researchers are studying whether rifampicin, an antibiotic, or itraconazole, an antifungal, change how the body handles vorolanib, an oral cancer drug. Thirty-six healthy volunteers take vorolanib alone, then again after several days of rifampicin or itraconazole. The trial measu…